Viagra(Sildenafil)For Sex CAS:139755-83-2
Viagra, generically known as sildenafil citrate, is a pharmaceutical breakthrough that revolutionized the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Since its FDA approval in 1998, it has become a household name, symbolizing hope for millions. This article delves into its unique pharmacology, applications, benefits, and lesser-known facets, offering fresh insights beyond standard descriptions.
What is Viagra? Beyond the Basics
Viagra was serendipitously discovered during clinical trials for angina (chest pain) in the 1990s. Researchers noted its unexpected side effect-enhanced erectile function-and pivoted to develop it as the first oral ED therapy.
Chemical Structure:
Sildenafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. Its molecular formula is C₂₂H₃₀N₆O₄S, featuring a pyrazolopyrimidinone core, which enables selective PDE5 binding. Unlike older ED treatments (e.g., injectables), its oral administration and rapid onset made it a game-changer.
Mechanism of Action:
●Nitric Oxide (NO) Pathway: Sexual stimulation triggers NO release in penile tissues, activating guanylate cyclase to produce cyclic guanosine monophosphate (cGMP).
●PDE5 Inhibition: Sildenafil blocks PDE5, an enzyme that degrades cGMP. Elevated cGMP relaxes smooth muscle cells in penile arteries, increasing blood flow for erection.
●Selectivity: While PDE5 is abundant in the lungs and penis, sildenafil's weak inhibition of PDE6 (retinal enzyme) explains rare visual disturbances.
Features: Beyond ED Treatment
Viagra's uniqueness lies in its dual therapeutic roles and off-label applications:
a. Approved Uses:
●Erectile Dysfunction: Restores physiological erectile response in 70–80% of men, regardless of ED etiology (diabetes, post-prostatectomy, psychological).
●Pulmonary Arterial Hypertension (PAH): Marketed as Revatio, it reduces pulmonary vascular resistance by dilating lung arteries, improving exercise capacity.
b. Off-Label Applications:
●Altitude Sickness: Studies suggest PDE5 inhibition improves oxygen saturation by vasodilating pulmonary vessels.
●Raynaud's Phenomenon: Enhances peripheral blood flow, reducing vasospastic attacks.
●Female Sexual Arousal Disorder: Investigational use, though evidence remains inconclusive.
c. Pharmacokinetic Profile:
●Onset: 30–60 minutes post-dose.
●Duration: 4–6 hours (prolonged with high-fat meals).
●Metabolism: Hepatic via CYP3A4; excreted in feces (80%) and urine (13%).
Benefits: Quality of Life and Beyond
Viagra's impact transcends physical effects:
●Psychological Relief: Reduces anxiety and depression linked to ED, restoring self-esteem.
●Relationship Dynamics: Improves intimacy, often resolving relational stress.
●PAH Survival: In PAH, it delays disease progression, reducing hospitalization rates.
Cost-Effectiveness: Post-patent expiration (2013), generics slashed prices by 95%, broadening accessibility.
Dosage: Precision for Safety and Efficacy
Tailored dosing optimizes outcomes:
a. Erectile Dysfunction:
●Standard: 50 mg, 1 hour pre-activity (range: 25–100 mg).
●Elderly/Comorbidities: Start at 25 mg to mitigate hypotension risks.
b. Pulmonary Arterial Hypertension:
●Revatio: 20 mg thrice daily (fixed schedule, unrelated to timing of activity).
c. Special Populations:
●Renal/Hepatic Impairment: Maximum 25 mg daily.
●Nitrate Users: Contraindicated due to life-threatening hypotension.
Cycle and Timing: Strategic Use
Viagra lacks a "cycle" like anabolic steroids but requires strategic timing:
●Intermittent Use: Taken "on-demand" for ED, avoiding daily dependency.
●Chronic Use: For PAH, strict adherence to TID dosing ensures sustained pulmonary benefits.
●Food Interactions: High-fat meals delay absorption by 1 hour; recommend fasting for optimal effect.
Half-Life and Metabolism: The Science of Duration
●Half-Life: ~4 hours (prolonged in elderly or hepatic impairment).
●Active Metabolite: N-desmethyl sildenafil (half-life: 24 hours) contributes to prolonged effects.
●Drug Interactions:
○CYP3A4 Inhibitors (e.g., erythromycin): Increase sildenafil levels.
○Alpha-Blockers: Synergistic hypotension risk.
Post-Treatment Considerations (PTC)
Discontinuation requires caution:
●Rebound ED: Psychological dependence may occur, necessitating counseling.
●PAH Rebound: Abrupt cessation risks pulmonary pressure spikes; taper under supervision.
Myths vs. Facts: Dispelling Misconceptions
●Myth: "Viagra is an aphrodisiac."
Fact: It requires sexual stimulation; no effect on libido.
●Myth: "Higher doses guarantee better erections."
Fact: Excess dosing increases side effects (headaches, priapism) without enhancing efficacy.
Adverse Effects: Rare but Critical
●Common: Headache (16%), flushing (10%), dyspepsia (7%).
●Serious: Priapism (<1%), sudden hearing/vision loss (FDA black box warning).
●Cardiovascular: Safe in stable CAD but avoid in recent stroke/MI.
Future Directions: Beyond ED and PAH
Ongoing research explores:
●Neuroprotection: cGMP's role in reducing neurodegenerative inflammation.
●Cancer: Enhancing chemotherapeutic drug delivery via vasodilation.
●Women's Health: Addressing sexual dysfunction post-menopause.
Clinical data
|
Product Name |
Viagra |
|
CAS |
139755-83-2 |
|
Molar mass |
474.6 |
|
MF |
C22H30N6O4S |
|
Purity |
Above 98% |
|
Apprarance |
White Tablet |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Viagra's legacy lies in its dual role as a medical and cultural icon. Its novel applications, patient-centric benefits, and evolving research underscore its enduring relevance. As science advances, sildenafil may yet unlock new therapeutic frontiers, reaffirming its status as a serendipitous marvel of modern medicine.
Hot Tags: Viagra(Sildenafil)For Sex CAS:139755-83-2, China Viagra(Sildenafil)For Sex CAS:139755-83-2 manufacturers, suppliers, factory
